Table 4.

Changes (Δ) in periodontal parameters of patients with RA who received medication with inhibitors of IL‐6 receptor and tumor necrosis factor.

Parameters	TCZ group (n = 20)	TNFI group (n = 40)	p‐value*
Δ GI	−0.21 ± 0.19	−0.11 ± 0.12	0.03 *
Δ % sites with plaque	−4.2 ± 20.6	−6.9 ± 16.5	0.81
Δ % sites with BOP	−6.3 ± 8.9	−3.7 ± 9.3	0.32
Δ PD (mm)	−0.12 ± 0.17	−0.14 ± 0.13	0.38
Δ % sites with PD ≥4 mm	−5.8 ± 13.4	−0.1 ± 17.4	0.82
Δ CAL (mm)	−0.07 ± 0.14	−0.02 ± 0.20	0.96
Δ % sites with CAL ≥4 mm	−2.9 ± 14.0	+2.8 ± 17.4	0.90

RA, rheumatoid arthritis; GI, gingival index; BOP, bleeding on probing; PD, probing depth; CAL, clinical attachment level; TCZ, tocilizumab; TNFI, tumor necrosis factor inhibitor; n, number.

Values represent the mean ± standard deviation changes from baseline to 6 months after medication (−: decrease and +: increase), and the bold values show the statistical significance.

^* Significantly different between the groups, as assessed by Mann–Whitney U‐test (p < 0.05).